skin cancer

https://pharmaphorum.com/news/nhs-funds-bms-opdivo-to-prevent-skin-cancer-returning/

Quality of life increasingly important in skin cancer, say doctors at this year’s ESMO

https://pharmaphorum.com/views-analysis-oncology/quality-of-life-increasingly-important-in-skin-cancer-esmo/

EU regulators back BMS’ Opdivo in new skin cancer use

https://pharmaphorum.com/news/eu-regulators-back-bms-opdivo-in-new-skin-cancer-use/

Incyte shares down sharply after phase 3 skin cancer trial failure

https://pharmaphorum.com/news/incyte-shares-down-sharply-after-phase-3-skin-cancer-trial-failure/

BMS files Opdivo in post-surgery setting

https://pharmaphorum.com/news/bms-looks-licence-opdivo-suppress-melanoma-surgery/

Biofrontera mulls US IPO to fund skin cancer drug

https://pharmaphorum.com/news/biofrontera-considers-us-listing-fund-skin-cancer-drug/

Merck KGaA and Pfizer break into cancer immunotherapy

https://pharmaphorum.com/news/merckpfizer-break-cancer-immunotherapy-avelumab-approval/

AI on par with dermatologists at diagnosing skin cancer

https://pharmaphorum.com/news/ai-par-dermatologists-diagnosing-skin-cancer/

Roche muscling into melanoma with Tecentriq

https://pharmaphorum.com/top-pharmaceutical-companies/roche/roche-plans-phase-3-skin-cancer-combination-trials-tecentriq/

1 2

Close in 10 seconds

Pharmaphorum.com

Search